AB 2821: Richard Paul Hemann Parkinson’s Disease Program.
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2020-09-18
|
Date
|
Status
|
|---|---|
| Sep 18, 2020 | Chaptered by Secretary of State - Chapter 103, Statutes of 2020. |
| Sep 18, 2020 | Approved by the Governor. |
| Sep 11, 2020 | Enrolled and presented to the Governor at 3 p.m. |
| Aug 30, 2020 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 75. Noes 0. Page 5316.). |
| Aug 28, 2020 | In Assembly. Concurrence in Senate amendments pending. |
| Aug 28, 2020 | Read third time. Passed. Ordered to the Assembly. (Ayes 39. Noes 0. Page 4385.). |
| Aug 26, 2020 | Ordered to special consent calendar. |
| Aug 24, 2020 | Read second time. Ordered to third reading. |
| Aug 20, 2020 | From committee: Amend, and do pass as amended. (Ayes 7. Noes 0.) (August 20). |
| Aug 13, 2020 | In committee: Referred to APPR. suspense file. |
| Aug 1, 2020 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 0.) (August 1). Re-referred to Com. on APPR. |
| Jul 1, 2020 | Referred to Com. on HEALTH. |
| Jun 11, 2020 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Jun 10, 2020 | Read third time. Passed. Ordered to the Senate. (Ayes 78. Noes 0. Page 4771.) |
| Jun 4, 2020 | Read second time. Ordered to third reading. |
| Jun 3, 2020 | From committee: Do pass. (Ayes 18. Noes 0.) (June 3). |
| Jun 2, 2020 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| May 19, 2020 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 15. Noes 0.) (May 18). Re-referred to Com. on APPR. |
| Mar 12, 2020 | Referred to Com. on HEALTH. |
| Feb 21, 2020 | From printer. May be heard in committee March 22. |
| Feb 20, 2020 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 30, 2020 | AB 2821 Nazarian Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 28, 2020 | Special Consent AB2821 | Senate Floor |
Passed |
|
| Aug 20, 2020 | Do pass as amended | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 13, 2020 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 1, 2020 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| Jun 10, 2020 | AB 2821 Nazarian Assembly Third Reading | Assembly Floor |
Passed |
|
| Jun 3, 2020 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| May 18, 2020 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 2821
Author:(Nazarian)
As Amended Ver: August 20, 2020
Majority vote
SUMMARY:
Extends to January 1, 2022, the sunset date of the Richard Paul Hemann Parkinson's Disease Program (PDP) which was established to require the Department of Public Health (DPH) to collect data on the incidence of Parkinson's disease in California.
The Senate Amendments:
Delete the January 1, 2026, sunset date of the PDP and instead extended it to January 1, 2022.
COMMENTS:
The PDP defines Parkinson's disease as a chronic and progressive neurologic disorder resulting from deficiency of the neurotransmitter dopamine as the consequence of degenerative, vascular, or inflammatory changes in the area of the brain called the basal ganglia. It is characterized by tremor at rest, slow movements, rigidity of movement, droopy posture, muscle weakness, and unsteady or shuffling gait. According to the Parkinson's Foundation, there are typical patterns of progression in Parkinson's disease that are defined in stages. During stage one or initial stage, a person has mild symptoms that generally do not interfere with daily activities. Tremor and other movement symptoms occur on one side of the body only. Changes in posture, walking and facial expressions occur. At stage two, symptoms start getting worse. Tremor, rigidity and other movement symptoms affect both sides of the body. Walking problems and poor posture may be apparent. The person is still able to live alone, but daily tasks are more difficult and lengthy. Stage three is considered mid-stage, loss of balance and slowness of movements are hallmarks. Falls are more common. The person is still fully independent, but symptoms significantly impair activities such as dressing and eating. Under stage four, symptoms are severe and limiting. It's possible to stand without assistance, but movement may require a walker. The person needs help with activities of daily living and is unable to live alone. Finally, stage five is the most advanced and debilitating stage. Stiffness in the legs may make it impossible to stand or walk. The person requires a wheelchair or is bedridden. Around-the-clock nursing care is required for all activities. The person may experience hallucinations and delusions. The Parkinson's community acknowledges that there are many important non-motor symptoms as well as motor symptoms.
The tracking of Parkinson's disease in California commenced with the passage of AB 2248 (Frommer), Chapter 945, Statutes of 2004, which required DPH to create a confidential list of persons diagnosed with Parkinson's for tracking and research purposes. According to an Assembly Budget Subcommittee agenda from May 2019, since AB 2248 was not funded by the State, a team of neurologists, scientists and epidemiologists at University of California – Los Angeles (UCLA), University of California – San Francisco (UCSF), the Parkinson's Institute, Stanford and Kaiser Permanente Division of Research were able to obtain seed money from the Michael J Fox Foundation, the National Institutes of Health and the Department of Defense to conduct a pilot project. The pilot project, which began in 2008, surveyed physicians, hospitals and pharmacies in order to identify all cases of Parkinson's disease in four counties: Fresno, Kern, Santa Clara and Tulare. The data from the four counties showed that geographic areas with the highest level of pesticide use also had the highest rates of Parkinson's disease. This data in concert with ongoing studies at UCLA and UCSF helped to establish that environmental toxins, including well-water pesticides, persistent pollutants such as pesticides and solvents present in our soil and water are linked to an increased risk of Parkinson's disease. It is reported that the pilot project was successful in establishing an infrastructure and best methods for developing a Parkinson's disease registry in four counties.
In 2017, the Legislature passed SB 97 (Committee on Budget and Fiscal Review), Chapter 52, Statutes of 2017, which augmented the budget of the pilot program by $1.7 million General Fund (GF) and established the California Parkinson's Disease Registry (CPDR) formally in statute (named as the Richard Paul Hemann Parkinson's Disease Program). The statewide CPDR launched on July 1, 2018. According to the Department of Finance, this funding was allocated for a period of three years. Only $340,000 of the $1 million appropriation for 2018-19 has been spent; however, all $1 million allocated for 2019-20 is projected to be spent. The 2019-20 Budget does not include additional resources. AB 715 (Nazarian), Chapter 806, Statutes of 2019, extended the CPDR to January 1, 2021.
According to DPH's website, as of March 9, 2020, the CPDR has received 222,708 records since mandated reporting began in July 1, 2018. DPH notes that the number of records reported to the CPDR does not represent the number of individual's with Parkinson's disease in California, and states that it continues to process registry data, including de-duplication of case records and other quality control measures.
According to the Author:
According to the author, Parkinson's disease is a chronic, progressive neurological disease. It is the second most common neurodegenerative disease in the United States and the 14th leading cause of death in the nation. Approximately 117,000 Californians have Parkinson's which costs the state $5.8 billion annually. It is estimated that over 1.5 million individuals in the United States suffer from Parkinson's disease, with 70,000 newly diagnosed cases per year. Surprisingly, little is known about how Parkinson's disease is dispersed between different demographics and whether the patterns of the disease are changing over time. The benefits of the California Cancer Registry, also managed by DPH, are well-known, having collected detailed information on over seven million cases of cancer among Californians diagnosed from 1988 on, with more than 175,000 new cases added annually. This information has helped determine where early detection, education, and research should be directed, which is ultimately the same mission of the Richard Paul Hemann Parkinson's Disease Program. The author concludes that this bill simply gives DPH more time to collect data using previously allocated funds that will help scientists identify patterns in Parkinson's disease in California, allowing for a better understanding of the causes of this disease and improved treatments.
Arguments in Support:
According to supporters, including the Michael J. Fox Foundation, sponsor of this bill, the American Parkinson's Disease Foundation and the Parkinson Association of Northern California, this bill is critical for many reasons including: helping identify high-risk groups, support patient contact studies, and serve as a valuable data resource to prevent and optimally manage Parkinson's disease; accurately determine incidence and prevalence of Parkinson's disease in California; help researchers study patterns of Parkinson's disease over time; and help determine if certain regions of the state that use more pesticides (based on California's pesticide registry) have higher incidents of Parkinson's.
Arguments in Opposition:
The California Academy of Family Physicians opposes this bill and states that before extending the sunset date on the program, DPH should go through a rigorous re-evaluation of the CPDR and whether or not it is achieving results in addressing a noncommunicable disease.
Arguments in Opposition unless Amended:
The California Medical Association has an oppose unless amended position and states that this bill should direct DPH to collect and report data on Parkinson's disease only until the Office of Statewide Health Planning and Development's Heath Care Payments Database is implemented.
FISCAL COMMENTS:
According to the Senate Appropriations Committee:
According to DPH, ongoing costs of $408,591 (General Fund) in FY 2021-22, for 2.0 positions (1.0 Research Scientist I and Research Scientist II), contracted resources, and to maintain the portal ($75,000). Staff notes cost pressures in the out-years in a like amount to extend the program beyond the sunset.
VOTES:
ASM HEALTH: 15-0-0
YES: Wood, Mayes, Aguiar-Curry, Bigelow, Bonta, Burke, Carrillo, Flora, Limón, McCarty, Nazarian, Ramos, Rodriguez, Santiago, Waldron
ASM APPROPRIATIONS: 18-0-0
YES: Gonzalez, Bigelow, Bauer-Kahan, Bloom, Bonta, Calderon, Carrillo, Chau, Megan Dahle, Diep, Eggman, Fong, Gabriel, Eduardo Garcia, Petrie-Norris, McCarty, Robert Rivas, Voepel
ASSEMBLY FLOOR: 78-0-1
YES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Mullin, Muratsuchi, Nazarian, O'Donnell, Obernolte, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
ABS, ABST OR NV: Quirk
SENATE FLOOR: 39-0-1
YES: Allen, Archuleta, Atkins, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dahle, Dodd, Durazo, Galgiani, Glazer, Lena Gonzalez, Grove, Hertzberg, Hill, Hueso, Hurtado, Jackson, Leyva, McGuire, Melendez, Mitchell, Monning, Moorlach, Morrell, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Umberg, Wieckowski, Wiener, Wilk
ABS, ABST OR NV: Jones
UPDATED:
VERSION: August 20, 2020
CONSULTANT: Rosielyn Pulmano / HEALTH / (916) 319-2097 FN: 0003294
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 2821 |
THIRD READING
Bill No: AB 2821
Author: Nazarian (D)
Amended: 8/20/20 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 8-0, 8/1/20
AYES: Pan, Lena Gonzalez, Grove, Hurtado, Leyva, Mitchell, Monning, Rubio
NO VOTE RECORDED: Melendez
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/20/20
AYES: Portantino, Bates, Bradford, Hill, Jones, Leyva, Wieckowski
ASSEMBLY FLOOR: 78-0, 6/10/20 - See last page for vote
SUBJECT: Richard Paul Hemann Parkinson’s Disease Program
SOURCE: The Michael J. Fox Foundation for Parkinson’s Research
DIGEST:
This bill extends the California Parkinson’s Disease Registry until January 1, 2022.
ANALYSIS:
Existing law:
- Establishes the Richard Paul Hemann Parkinson’s Disease Program (referred to as the California Parkinson’s Disease Registry or CPDR), which, among other things, requires the Department of Public Health (DPH) to collect data on the incidence and prevalence of Parkinson’s disease in California. [HSC §103870, et seq.]
- Requires a hospital, facility, physician, or other health care provider diagnosing or providing treatment to Parkinson’s disease patients to report each case to DPH, as prescribed. [HSC §103870(d)]
- Requires physicians, hospitals, outpatient clinics, and all other facilities, individuals, or agencies providing diagnostic or treatment services to patients with Parkinson’s disease to grant DPH or an authorized representative access to all records that would identify cases of Parkinson’s disease or would establish characteristics of Parkinson’s disease, treatment of Parkinson’s disease, or medical status of any identified Parkinson’s disease patient. [HSC §103870(f)]
- Conditions the implementation of CPDR on the availability of funds and repeals the program on January 1, 2021. [HSC §103870(h), 103870.2]
This bill extends CPDR until January 1, 2022.
Comments
- Author’s statement. According to the author, Parkinson’s disease is a chronic, progressive neurological disease. It is the second most common neurodegenerative disease in the United States and the 14th leading cause of death in the nation. Approximately 117,000 Californians have Parkinson’s which costs the state $5.8 billion annually. It is estimated that over 1.5 million individuals in the United States suffer from Parkinson’s disease, with 70,000 newly diagnosed cases per year. Surprisingly, little is known about how Parkinson’s disease is dispersed between different demographics and whether the patterns of the disease are changing over time. The benefits of the California Cancer Registry, also managed by DPH, are well-known, having collected detailed information on over seven million cases of cancer among Californians diagnosed from 1988 on, with more than 175,000 new cases added annually. This information has helped determine where early detection, education, and research should be directed, which is ultimately the same mission of the Richard Paul Hemann Parkinson’s Disease Program. This bill simply gives DPH more time to collect data using previously allocated funds that will help scientists identify patterns in Parkinson’s disease in California, allowing for a better understanding of the causes of this disease and improved treatments.
- Parkinson’s disease. According to the National Institute on Aging, Parkinson's disease is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination. Parkinson's symptoms usually begin gradually and get worse over time and as the disease progresses, people may have difficulty walking and talking. They may also have mental and behavioral changes, sleep problems, depression, memory difficulties, and fatigue. Parkinson’s affects about 50% more men than women. Although most people with Parkinson’s first develop the disease at about age 60, about 5% to 10% of people with Parkinson's have "early-onset" disease, which begins before the age of 50. Parkinson's disease occurs when nerve cells in an area of the brain that controls movement become impaired and/or die. When the neurons die or become impaired, they produce less dopamine, which causes the movement problems of Parkinson's. People with Parkinson's also lose the nerve endings that produce norepinephrine, the main chemical messenger of the sympathetic nervous system, which controls many automatic functions of the body, such as heart rate and blood pressure. The loss of norepinephrine might help explain some of the non-movement features of Parkinson's, such as fatigue, irregular blood pressure, decreased movement of food through the digestive tract, and sudden drop in blood pressure when a person stands up from a sitting or lying-down position. Although some cases of Parkinson's appear to be hereditary, and a few can be traced to specific genetic mutations, in most cases the disease occurs randomly and does not seem to run in families. Many researchers now believe that Parkinson's disease results from a combination of genetic factors and environmental factors such as exposure to toxins. Although there is no cure for Parkinson's disease, medicines, surgical treatment, and other therapies can often relieve some symptoms.
- CPDR. AB 2248 (Frommer, Chapter 945, Statutes of 2004) required DPH to create a confidential list of persons diagnosed with Parkinson’s for tracking and research purposes. According to an Assembly Budget Subcommittee agenda from May 2019, since AB 2248 was not funded by the State, a team of neurologists, scientists and epidemiologists at University of California – Los Angeles (UCLA), University of California – San Francisco (UCSF), the Parkinson’s Institute, Stanford and Kaiser Permanente Division of Research were able to obtain seed money from the Michael J Fox Foundation, the National Institutes of Health and the Department of Defense to conduct a pilot project. The pilot project, which began in 2008, surveyed physicians, hospitals and pharmacies in order to identify all cases of Parkinson’s disease in four counties: Fresno, Kern, Santa Clara and Tulare. The data from the four counties showed that geographic areas with the highest level of pesticide use also had the highest rates of Parkinson’s disease. This data in concert with ongoing studies at UCLA and UCSF helped to establish that environmental toxins, including well-water pesticides, persistent pollutants such as pesticides and solvents present in our soil and water are linked to an increased risk of Parkinson’s disease. It is reported that the pilot project was successful in establishing an infrastructure and best methods for developing a Parkinson’s disease registry in four counties.
The Legislature augmented the budget by $1.7 million General Fund and established the statewide CPDR formally in statute (named as the Richard Paul Hemann Parkinson’s Disease Program) through SB 97 (Committee on Budget and Fiscal Review, Chapter 52, Statutes of 2017). The statewide CPDR launched on July 1, 2018. According to the Department of Finance, this funding was allocated for a period of three years. Only $340,000 of the $1 million appropriation for 2018-19 was spent; and virtually all of the $1 million allocated for 2019-20 was spent. The 2020-21 Budget did not include additional resources. AB 715 (Nazarian, Chapter 806, Statutes of 2019) extended the CPDR to January 1, 2021. The Michael J. Fox Foundation, the sponsor of this bill, has committed to providing $400,000 for support of CPDR from July 2020 through July 2021.
- CPDR data. According to DPH’s website, as of March 9, 2020, the CPDR has received 222,708 records since mandated reporting began in July 2018. DPH notes that the number of records reported to the CPDR does not represent the number of individuals with Parkinson’s disease in California, and states that it continues to process registry data, including de-duplication of case records and other quality control measures.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee:
- According to DPH, ongoing costs of $408,591 (General Fund) in FY 2021-22 for 2.0 positions (1.0 Research Scientist I and Research Scientist II), contracted resources, and to maintain the portal ($75,000).
SUPPORT: (Verified 8/20/20)
The Michael J. Fox Foundation for Parkinson’s Research (source)
ALS Association Golden West Chapter
American Academy of Neurology
American Parkinson’s Disease Association
California Life Sciences Association
California Parkinson’s disease Community
Parkinson and Movement Disorder Alliance
Parkinson Association of Northern California
Parkinson’s Foundation
PD Active
OPPOSITION: (Verified 8/20/20)
California Academy of Family Physicians
California Medical Association
ARGUMENTS IN SUPPORT: According to supporters, including the Michael J. Fox Foundation, sponsor of this bill, the American Parkinson’s Disease Foundation and the Parkinson Association of Northern California, this bill is critical for many reasons including: helping identify high-risk groups, support patient contact studies, and serve as a valuable data resource to prevent and optimally manage Parkinson’s disease; accurately determine incidence and prevalence of Parkinson’s disease in California; help researchers study patterns of Parkinson’s disease over time; and help determine if certain regions of the state that use more pesticides (based on CA’s pesticide registry) have higher incidents of Parkinson’s.
ARGUMENTS IN OPPOSITION: The California Academy of Family Physicians opposes this bill and states that before extending the sunset date on the program, DPH should go through a rigorous re-evaluation of the CPDR and whether or not it is achieving results in addressing a noncommunicable disease.
The California Medical Association has an oppose unless amended position and states that this bill should direct DPH to collect and report data on Parkinson’s disease only until the Office of Statewide Health Planning and Development’s (OSHPD) Heath Care Payments Database is implemented.
ASSEMBLY FLOOR: 78-0, 6/10/20
AYES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
NO VOTE RECORDED: Quirk
Prepared by: Melanie Moreno / HEALTH / (916) 651-4111
8/25/20 10:16:11
SENATE COMMITTEE ON
Senator Anthony Portantino, Chair
2019 - 2020 Regular Session
AB 2821 (Nazarian) - Richard Paul Hemann Parkinson’s Disease Program
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
*********** ANALYSIS ADDENDUM – SUSPENSE FILE ***********
The following information is revised to reflect amendments
adopted by the committee on August 20, 2020
Bill Summary:
AB 2821 would extend the sunset date for the Richard Paul Hemann Parkinson’s Disease Program from January 1, 2021, to January 1, 2026.
Fiscal Impact:
According to the Department of Public Health (CDPH), ongoing costs of $408,591 (General Fund) in FY 2021-22, for 2.0 positions (1.0 Research Scientist I and Research Scientist II), contracted resources, and to maintain the portal ($75,000). Staff notes cost pressures in the out-years in a like amount to extend the program beyond the sunset.
Committee Amendments:
The committee amendment would extend the sunset by one-year.
-- END --
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anthony Portantino, Chair
2019 - 2020 Regular Session
AB 2821 (Nazarian) - Richard Paul Hemann Parkinson’s Disease Program
Version: February 20, 2020 | Policy Vote: HEALTH 8 - 0 |
Urgency: No | Mandate: No |
Hearing Date: August 13, 2020 | Consultant: Samantha Lui |
Bill Summary:
AB 2821 would extend the sunset date for the Richard Paul Hemann Parkinson’s Disease Program from January 1, 2021, to January 1, 2026.
Fiscal Impact:
According to the Department of Public Health (CDPH), ongoing costs of $408,591 (General Fund) in FY 2021-22, and annually ongoing, for 2.0 positions (1.0 Research Scientist I and Research Scientist II), contracted resources, and to maintain the portal ($75,000). For additional detail, please see Staff Comments.
Background:
Parkinson’s disease is a brain disorder, caused when nerve cells in an area of the brain that control movement become impaired. As a result of those neurons being compromised, shaking, stiffness, and difficulty with balance and coordination occur. Symptoms usually begin gradually and worsen over time. Although most individuals diagnose with Parkinson’s disease first develop the disease at about age 60, about five to ten percent of individuals have early onset at age 50. According to the CDPH, however, little is known about how Parkinson’s disease is distributed among different population groups and other disease patterns.
AB 2248 (Frommer), Chapter 945, Statutes of 2004, requires CDPH to establish a Parkinson’s disease registry to track incidence and prevalence, to the extent federal funds or private sources supported the program. Senate Bill 97 (Committee on Budget and Fiscal Review), Chapter 52, Statutes of 2017, provided $1.7 million General Fund over three years to the statewide Richard Paul Hemann Parkinson’s Disease Program (also known as the Parkinson’s Disease Registry [CPDR]), and required health care providers that diagnose or provide treatment of Parkinson’s, a hospital, or facility to report each case of the disease to CDPH, effective July 1, 2018. The health trailer bill established a January 1, 2020 sunset. The statewide CPDR was launched on July 1, 2018. The appropriation amount was spent: $340,000 in FY 2018-19 and nearly all of the $1 million allocated for FY 2019-20. The 2020-21 Budget did not include additional resources.
The Michael J. Fox Foundation (MJFF) committed to providing $400,000 for support of CPDR from July 2020 through July 2021.
Proposed Law:
AB 2821 would extend the sunset date for the Richard Paul Hemann Parkinson’s Disease Program from January 1, 2021, to January 1, 2026.
Related Legislation:
Assembly Bill 715 (Nazarian, Chapter 806, Statutes of 2019) would extend the Richard Paul Hemaan Parkinson’s Disease Program from January 1, 2020, to January 1, 2021.
Staff Comments:
The CDPH notes the fiscal estimate assumes an average of 150,000 records (based on records received between July 2018 – December 2019 would be received and processed annually. The 2.0 anticipated positions would:
- 1.0 Research Scientist II ($184,591) would ensure data adjudication, quality control, and responds to external data requests.
- 1.0 Research Scientist I ($149,000) to ensure data quality through monitoring and and data de-duplication.
- The contracted technical services would support the maintenance of the current data reporting channels (either through the electronic interface or the department’s California Reportable Disease Information Exchange database.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Richard Pan, Chair
BILL NO: AB 2821
AUTHOR: | Nazarian | ||
VERSION: | February 20, 2020 | ||
HEARING DATE: | August 1, 2020 | ||
CONSULTANT: | Melanie Moreno | ||
SUBJECT: Richard Paul Hemann Parkinson’s Disease Program.
SUMMARY:
Extends the California Parkinson’s Disease Registry until January 1, 2026.
Existing law:
- Establishes the Richard Paul Hemann Parkinson’s Disease Program (referred to as the California Parkinson’s Disease Registry or CPDR), which, among other things, requires the Department of Public Health (DPH) to collect data on the incidence and prevalence of Parkinson’s disease in California. [HSC §103870, et seq.]
- Requires a hospital, facility, physician, or other health care provider diagnosing or providing treatment to Parkinson’s disease patients to report each case to DPH, as prescribed. [HSC §103870(d)]
- Requires physicians, hospitals, outpatient clinics, and all other facilities, individuals, or agencies providing diagnostic or treatment services to patients with Parkinson’s disease to grant DPH or an authorized representative access to all records that would identify cases of Parkinson’s disease or would establish characteristics of Parkinson’s disease, treatment of Parkinson’s disease, or medical status of any identified Parkinson’s disease patient. [HSC §103870(f)]
- Conditions the implementation of CPDR on the availability of funds and repeals the program on January 1, 2021. [HSC §103870(h), 103870.2]
This bill: Extends CPDR until January 1, 2026.
FISCAL EFFECT:
According to Assembly Appropriations Committee, cost pressure of approximately $400,000 General Fund per year for an additional five years to DPH for staff and contract costs to continue operating the registry.
PRIOR VOTES:
Assembly Floor: | 78 - 0 |
Assembly Appropriations Committee: | 18 - 0 |
Assembly Health Committee: | 15 - 0 |
COMMENTS:
- Author’s statement. According to the author, Parkinson’s disease is a chronic, progressive neurological disease. It is the second most common neurodegenerative disease in the United States and the 14th leading cause of death in the nation. Approximately 117,000 Californians have Parkinson’s which costs the state $5.8 billion annually. It is estimated that over 1.5 million individuals in the United States suffer from Parkinson’s disease, with 70,000 newly diagnosed cases per year. Surprisingly, little is known about how Parkinson’s disease is dispersed between different demographics and whether the patterns of the disease are changing over time. The benefits of the California Cancer Registry, also managed by DPH, are well-known, having collected detailed information on over seven million cases of cancer among Californians diagnosed from 1988 on, with more than 175,000 new cases added annually. This information has helped determine where early detection, education, and research should be directed, which is ultimately the same mission of the Richard Paul Hemann Parkinson’s Disease Program. This bill simply gives DPH more time to collect data using previously allocated funds that will help scientists identify patterns in Parkinson’s disease in California, allowing for a better understanding of the causes of this disease and improved treatments.
- Background. According to the National Institute on Aging, Parkinson's disease is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination. Parkinson's symptoms usually begin gradually and get worse over time and as the disease progresses, people may have difficulty walking and talking. They may also have mental and behavioral changes, sleep problems, depression, memory difficulties, and fatigue. Parkinson’s affects about 50% more men than women. Although most people with Parkinson’s first develop the disease at about age 60, about 5% to 10% of people with Parkinson's have "early-onset" disease, which begins before the age of 50. Parkinson's disease occurs when nerve cells in an area of the brain that controls movement become impaired and/or die. When the neurons die or become impaired, they produce less dopamine, which causes the movement problems of Parkinson's. People with Parkinson's also lose the nerve endings that produce norepinephrine, the main chemical messenger of the sympathetic nervous system, which controls many automatic functions of the body, such as heart rate and blood pressure. The loss of norepinephrine might help explain some of the non-movement features of Parkinson's, such as fatigue, irregular blood pressure, decreased movement of food through the digestive tract, and sudden drop in blood pressure when a person stands up from a sitting or lying-down position. Although some cases of Parkinson's appear to be hereditary, and a few can be traced to specific genetic mutations, in most cases the disease occurs randomly and does not seem to run in families. Many researchers now believe that Parkinson's disease results from a combination of genetic factors and environmental factors such as exposure to toxins. Although there is no cure for Parkinson's disease, medicines, surgical treatment, and other therapies can often relieve some symptoms.
- CPDR. AB 2248 (Frommer, Chapter 945, Statutes of 2004) required DPH to create a confidential list of persons diagnosed with Parkinson’s for tracking and research purposes. According to an Assembly Budget Subcommittee agenda from May 2019, since AB 2248 was not funded by the State, a team of neurologists, scientists and epidemiologists at University of California – Los Angeles (UCLA), University of California – San Francisco (UCSF), the Parkinson’s Institute, Stanford and Kaiser Permanente Division of Research were able to obtain seed money from the Michael J Fox Foundation, the National Institutes of Health and the Department of Defense to conduct a pilot project. The pilot project, which began in 2008, surveyed physicians, hospitals and pharmacies in order to identify all cases of Parkinson’s disease in four counties: Fresno, Kern, Santa Clara and Tulare. The data from the four counties showed that geographic areas with the highest level of pesticide use also had the highest rates of Parkinson’s disease. This data in concert with ongoing studies at UCLA and UCSF helped to establish that environmental toxins, including well-water pesticides, persistent pollutants such as pesticides and solvents present in our soil and water are linked to an increased risk of Parkinson’s disease. It is reported that the pilot project was successful in establishing an infrastructure and best methods for developing a Parkinson’s disease registry in four counties.
The Legislature augmented the budget by $1.7 million General Fund and established the statewide CPDR formally in statute (named as the Richard Paul Hemann Parkinson’s Disease Program) through SB 97 (Committee on Budget and Fiscal Review, Chapter 52, Statutes of 2017). The statewide CPDR launched on July 1, 2018. According to the Department of Finance, this funding was allocated for a period of three years. Only $340,000 of the $1 million appropriation for 2018-19 was spent; and virtually all of the $1 million allocated for 2019-20 was spent. The 2020-21 Budget did not include additional resources. AB 715 (Nazarian), Chapter 806, Statutes of 2019, extended the CPDR to January 1, 2021. The Michael J. Fox Foundation (MJFF), the sponsor of this bill, has committed to providing $400,000 for support of CPDR from July 2020 through July 2021.
- CPDR data. According to DPH’s website, as of March 9, 2020, the CPDR has received 222,708 records since mandated reporting began in July 2018. DPH notes that the number of records reported to the CPDR does not represent the number of individuals with Parkinson’s disease in California, and states that it continues to process registry data, including de-duplication of case records and other quality control measures.
- Support. According to supporters, including the Michael J. Fox Foundation, sponsor of this bill, the American Parkinson’s Disease Foundation and the Parkinson Association of Northern California, this bill is critical for many reasons including: helping identify high-risk groups, support patient contact studies, and serve as a valuable data resource to prevent and optimally manage Parkinson’s disease; accurately determine incidence and prevalence of Parkinson’s disease in California; help researchers study patterns of Parkinson’s disease over time; and help determine if certain regions of the state that use more pesticides (based on CA’s pesticide registry) have higher incidents of Parkinson’s.
- Opposition. The California Academy of Family Physicians opposes this bill and states that before extending the sunset date on the program, DPH should go through a rigorous re-evaluation of the CPDR and whether or not it is achieving results in addressing a noncommunicable disease.
- Oppose unless amended. The California Medical Association has an oppose unless amended position and states that this bill should direct DPH to collect and report data on Parkinson’s disease only until the Office of Statewide Health Planning and Development’s (OSHPD) Heath Care Payments Database is implemented.
SUPPORT AND OPPOSITION:
Support: The Michael J. Fox Foundation for Parkinson’s Research (sponsor)
ALS Association Golden West Chapter
American Academy of Neurology
American Parkinson Disease Association
California Life Sciences Association
California Parkinson’s disease Community
PD Active
Parkinson Association of Northern California
Parkinson’s Foundation
Parkinson and Movement Disorder Alliance
Oppose: California Academy of Family Physicians
California Medical Association (unless amended)
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 2821
Author:(Nazarian)
As Introduced Ver:February 20, 2020
Majority vote
SUMMARY:
Extends to January 1, 2026, the sunset date of the Richard Paul Hemann Parkinson's Disease Program (PDP) which was established to require the Department of Public Health (DPH) to collect data on the incidence of Parkinson's disease in California.
Major Provisions
COMMENTS:
The PDP defines Parkinson's disease as a chronic and progressive neurologic disorder resulting from deficiency of the neurotransmitter dopamine as the consequence of degenerative, vascular, or inflammatory changes in the area of the brain called the basal ganglia. It is characterized by tremor at rest, slow movements, rigidity of movement, droopy posture, muscle weakness, and unsteady or shuffling gait. According to the Parkinson's Foundation, there are typical patterns of progression in Parkinson's disease that are defined in stages. During stage one or initial stage, a person has mild symptoms that generally do not interfere with daily activities. Tremor and other movement symptoms occur on one side of the body only. Changes in posture, walking and facial expressions occur. At stage two, symptoms start getting worse. Tremor, rigidity and other movement symptoms affect both sides of the body. Walking problems and poor posture may be apparent. The person is still able to live alone, but daily tasks are more difficult and lengthy. Stage three is considered mid-stage, loss of balance and slowness of movements are hallmarks. Falls are more common. The person is still fully independent, but symptoms significantly impair activities such as dressing and eating. Under stage four, symptoms are severe and limiting. It's possible to stand without assistance, but movement may require a walker. The person needs help with activities of daily living and is unable to live alone. Finally, stage five is the most advanced and debilitating stage. Stiffness in the legs may make it impossible to stand or walk. The person requires a wheelchair or is bedridden. Around-the-clock nursing care is required for all activities. The person may experience hallucinations and delusions. The Parkinson's community acknowledges that there are many important non-motor symptoms as well as motor symptoms.
The tracking of Parkinson's disease in California commenced with the passage of AB 2248 (Frommer), Chapter 945, Statutes of 2004, which required DPH to create a confidential list of persons diagnosed with Parkinson's for tracking and research purposes. According to an Assembly Budget Subcommittee agenda from May 2019, since AB 2248 was not funded by the State, a team of neurologists, scientists and epidemiologists at University of California – Los Angeles (UCLA), University of California – San Francisco (UCSF), the Parkinson's Institute, Stanford and Kaiser Permanente Division of Research were able to obtain seed money from the Michael J Fox Foundation, the National Institutes of Health and the Department of Defense to conduct a pilot project. The pilot project, which began in 2008, surveyed physicians, hospitals and pharmacies in order to identify all cases of Parkinson's disease in four counties: Fresno, Kern, Santa Clara and Tulare. The data from the four counties showed that geographic areas with the highest level of pesticide use also had the highest rates of Parkinson's disease. This data in concert with ongoing studies at UCLA and UCSF helped to establish that environmental toxins, including well-water pesticides, persistent pollutants such as pesticides and solvents present in our soil and water are linked to an increased risk of Parkinson's disease. It is reported that the pilot project was successful in establishing an infrastructure and best methods for developing a Parkinson's disease registry in four counties.
In 2017, the Legislature passed SB 97 (Committee on Budget and Fiscal Review), Chapter 52, Statutes of 2017, which augmented the budget of the pilot program by $1.7 million General Fund (GF) and established the California Parkinson's Disease Registry (CPDR) formally in statute (named as the Richard Paul Hemann Parkinson's Disease Program). The statewide CPDR launched on July 1, 2018. According to the Department of Finance, this funding was allocated for a period of three years. Only $340,000 of the $1 million appropriation for 2018-19 has been spent; however, all $1 million allocated for 2019-20 is projected to be spent. The 2019-20 Budget does not include additional resources. AB 715 (Nazarian), Chapter 806, Statutes of 2019, extended the CPDR to January 1, 2021.
According to DPH's website, as of March 9, 2020, the CPDR has received 222,708 records since mandated reporting began in July 1, 2018. DPH notes that the number of records reported to the CPDR does not represent the number of individual's with Parkinson's disease in California, and states that it continues to process registry data, including de-duplication of case records and other quality control measures.
According to the Author:
According to the author, Parkinson's disease is a chronic, progressive neurological disease. It is the second most common neurodegenerative disease in the United States and the 14th leading cause of death in the nation. Approximately 117,000 Californians have Parkinson's which costs the state $5.8 billion annually. It is estimated that over 1.5 million individuals in the United States suffer from Parkinson's disease, with 70,000 newly diagnosed cases per year. Surprisingly, little is known about how Parkinson's disease is dispersed between different demographics and whether the patterns of the disease are changing over time. The benefits of the California Cancer Registry, also managed by DPH, are well-known, having collected detailed information on over seven million cases of cancer among Californians diagnosed from 1988 on, with more than 175,000 new cases added annually. This information has helped determine where early detection, education, and research should be directed, which is ultimately the same mission of the Richard Paul Hemann Parkinson's Disease Program. The author concludes that this bill simply gives DPH more time to collect data using previously allocated funds that will help scientists identify patterns in Parkinson's disease in California, allowing for a better understanding of the causes of this disease and improved treatments.
Arguments in Support:
According to supporters, including the Michael J. Fox Foundation, sponsor of this bill, the American Parkinson's Disease Foundation and the Parkinson Association of Northern California, this bill is critical for many reasons including: helping identify high-risk groups, support patient contact studies, and serve as a valuable data resource to prevent and optimally manage Parkinson's disease; accurately determine incidence and prevalence of Parkinson's disease in California; help researchers study patterns of Parkinson's disease over time; and help determine if certain regions of the state that use more pesticides (based on California's pesticide registry) have higher incidents of Parkinson's.
Arguments in Opposition:
The California Academy of Family Physicians opposes this bill and states that before extending the sunset date on the program, DPH should go through a rigorous re-evaluation of the CPDR and whether or not it is achieving results in addressing a noncommunicable disease.
Arguments in Opposition unless Amended:
The California Medical Association has an oppose unless amended position and states that this bill should direct DPH to collect and report data on Parkinson's disease only until the Office of Statewide Health Planning and Development's Heath Care Payments Database is implemented.
FISCAL COMMENTS:
According to Assembly Appropriations Committee, cost pressure of approximately $400,000 General Fund per year for an additional five years to DPH for staff and contract costs to continue operating the registry.
VOTES:
ASM HEALTH: 15-0-0
YES: Wood, Mayes, Aguiar-Curry, Bigelow, Bonta, Burke, Carrillo, Flora, Limón, McCarty, Nazarian, Ramos, Rodriguez, Santiago, Waldron
ASM APPROPRIATIONS: 18-0-0
YES: Gonzalez, Bigelow, Bauer-Kahan, Bloom, Bonta, Calderon, Carrillo, Chau, Megan Dahle, Diep, Eggman, Fong, Gabriel, Eduardo Garcia, Petrie-Norris, McCarty, Robert Rivas, Voepel
UPDATED:
VERSION: February 20, 2020
CONSULTANT: Rosielyn Pulmano / HEALTH / (916) 319-2097 FN: 0002888
Date of Hearing: June 2, 2020
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 2821
Author:(Nazarian) – As Introduced Ver:February 20, 2020
Policy Committee: | Health | Vote: | 15 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill extends to January 1, 2026, the sunset date of a disease registry established to collect data on Parkinson’s disease.
FISCAL EFFECT:
Cost pressure of approximately $400,000 GF per year for an additional five years to the California Department of Public Health (CDPH) for staff and contract costs to continue operating the registry.
COMMENTS:
- Purpose. According to the author, little is known about the demographics and trends in Parkinson’s disease, a chronic neurodegenerative disease that affects 1.5 million Americans. The author indicates this bill is needed to continue collecting data that will allow improved understanding of Parkinson’s disease, including causes and demographic trends.
- Program History. The 2017 Health trailer bill, SB 97 (Committee on Budget and Fiscal Review), Chapter 52, Statutes of 2017, established the statewide registry (named the Richard Paul Hemann Parkinson’s Disease Program). Prior to this, CDPH was authorized to collect data but no formal registry existed. The 2017 Budget Act allocated $1.7 million to the registry, which launched on July 1, 2018. AB 715 (Nazarian), Chapter 806, Statutes of 2019, extended the sunset of the registry for one additional year to January 1, 2021.
The registry collects confidential data used to study the incidence and prevalence of Parkinson's disease across California. This registry is modeled after the California Cancer Registry and is intended to collect data necessary to enhance early detection and to inform the direction of education and research regarding Parkinson's disease. Healthcare professionals diagnosing patients with or treating patients for Parkinson's disease are required to submit this information to CDPH.
According to CDPH’s website, as of March 9, 2020, the registry has received over 220,000 records since mandated reporting began in July 1, 2018. The program is set to sunset January 1, 2020, thus ending the requirement that entities report this information to DPH.
- Support and Opposition. According to supporters, including the Michael J. Fox Foundation, sponsor of this bill, the American Parkinson’s Disease Foundation and the Parkinson Association of Northern California, this bill is important to identify trends and high-risk groups and help track and manage the disease in California. The California Medical Association has an oppose unless amended position and states that this bill should direct CDPH to collect and report data on Parkinson’s disease only until a health care payments database is implemented by the Office of Statewide Health Planning and Development (scheduled for 2023). The California Academy of Family Physicians opposes this bill, arguing the program should be rigorously evaluated to see if it is achieving the desired results.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: May 18, 2020
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 2821
Author:(Nazarian) – As Introduced Ver:February 20, 2020
SUBJECT: Richard Paul Hemann Parkinson’s Disease Program.
SUMMARY: Extends to January 1, 2026, the sunset date of the Richard Paul Hemann Parkinson’s Disease Program (PDP) which was established to require the Department of Public Health (DPH) to collect data on the incidence of Parkinson’s disease in California.
EXISTING LAW:
- Establishes DPH to protect and improve the health of communities through education, promotion of healthy lifestyles, and research for disease and injury prevention.
- Establishes the California Parkinson’s Registry (also known as the Richard Paul Hemann California Parkinson’s Disease Registry (CPDR)) within the Chronic Disease Surveillance and Research Branch of DPH.
- Establishes the PDP to establish a system for the collection of information determining the incidence and prevalence of Parkinson’s disease.
- Requires the reporting to DPH all cases of Parkinson’s disease diagnosed or treated in California. Applies this reporting requirement to a hospital, facility, physician and surgeon, or other health care providers diagnosing or providing treatment to Parkinson’s disease patients (required reporters).
- Grants to DPH access to records of required reporters that would identify cases or would establish characteristic of Parkinson’s disease, treatment or medical status of any identified Parkinson’s disease patient. States that failure to grants access to records is punishable by a civil penalty of $500 each day that access is refused.
- Provides that all information collected under the PDP is confidential.
- Permits persons with a valid scientific interest who are engaged in demographic, epidemiological, or other similar studies related to health who meet qualifications as determined by DPH, and who agree, in writing, to maintain confidentiality, may be authorized access to the PDP’s confidential information collected by the department if certain requirements are met.
- Sunsets the PDP on January 1, 2021.
FISCAL EFFECT: This bill has not been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, Parkinson’s disease is a chronic, progressive neurological disease. It is the second most common neurodegenerative disease in the United States and the 14th leading cause of death in the nation. Approximately 117,000 Californians have Parkinson’s which costs the state $5.8 billion annually. It is estimated that over 1.5 million individuals in the United States suffer from Parkinson’s disease, with 70,000 newly diagnosed cases per year. Surprisingly, little is known about how Parkinson’s disease is dispersed between different demographics and whether the patterns of the disease are changing over time. The benefits of the California Cancer Registry, also managed by DPH, are well-known, having collected detailed information on over seven million cases of cancer among Californians diagnosed from 1988 on, with more than 175,000 new cases added annually. This information has helped determine where early detection, education, and research should be directed, which is ultimately the same mission of the Richard Paul Hemann Parkinson’s Disease Program. The author concludes that this bill simply gives DPH more time to collect data using previously allocated funds that will help scientists identify patterns in Parkinson’s disease in California, allowing for a better understanding of the causes of this disease and improved treatments.
- BACKGROUND. The PDP defines Parkinson’s disease as a chronic and progressive neurologic disorder resulting from deficiency of the neurotransmitter dopamine as the consequence of degenerative, vascular, or inflammatory changes in the area of the brain called the basal ganglia. It is characterized by tremor at rest, slow movements, rigidity of movement, droopy posture, muscle weakness, and unsteady or shuffling gait. According to the Parkinson’s Foundation, there are typical patterns of progression in Parkinson’s disease that are defined in stages. During stage one or initial stage, a person has mild symptoms that generally do not interfere with daily activities. Tremor and other movement symptoms occur on one side of the body only. Changes in posture, walking and facial expressions occur. At stage two, symptoms start getting worse. Tremor, rigidity and other movement symptoms affect both sides of the body. Walking problems and poor posture may be apparent. The person is still able to live alone, but daily tasks are more difficult and lengthy. Stage three is considered mid-stage, loss of balance and slowness of movements are hallmarks. Falls are more common. The person is still fully independent, but symptoms significantly impair activities such as dressing and eating. Under stage four, symptoms are severe and limiting. It’s possible to stand without assistance, but movement may require a walker. The person needs help with activities of daily living and is unable to live alone. Finally, stage five is the most advanced and debilitating stage. Stiffness in the legs may make it impossible to stand or walk. The person requires a wheelchair or is bedridden. Around-the-clock nursing care is required for all activities. The person may experience hallucinations and delusions. The Parkinson’s community acknowledges that there are many important non-motor symptoms as well as motor symptoms.
The tracking of Parkinson’s disease in California commenced with the passage of AB 2248 (Frommer), Chapter 945, Statutes of 2004, which required DPH to create a confidential list of persons diagnosed with Parkinson’s for tracking and research purposes. According to an Assembly Budget Subcommittee agenda from May 2019, since AB 2248 was not funded by the State, a team of neurologists, scientists and epidemiologists at University of California – Los Angeles (UCLA), University of California – San Francisco (UCSF), the Parkinson’s Institute, Stanford and Kaiser Permanente Division of Research were able to obtain seed money from the Michael J Fox Foundation, the National Institutes of Health and the Department of Defense to conduct a pilot project. The pilot project, which began in 2008, surveyed physicians, hospitals and pharmacies in order to identify all cases of Parkinson’s disease in four counties: Fresno, Kern, Santa Clara and Tulare. The data from the four counties showed that geographic areas with the highest level of pesticide use also had the highest rates of Parkinson’s disease. This data in concert with ongoing studies at UCLA and UCSF helped to establish that environmental toxins, including well-water pesticides, persistent pollutants such as pesticides and solvents present in our soil and water are linked to an increased risk of Parkinson’s disease. It is reported that the pilot project was successful in establishing an infrastructure and best methods for developing a Parkinson’s disease registry in four counties.
In 2017, the Legislature passed SB 97 (Committee on Budget and Fiscal Review), Chapter 52, Statutes of 2017, which augmented the budget of the pilot program by $1.7 million General Fund and established the statewide CPDR formally in statute (named as the Richard Paul Hemann Parkinson’s Disease Program). The statewide CPDR launched on July 1, 2018. According to the Department of Finance, this funding was allocated for a period of three years. Only $340,000 of the $1 million appropriation for 2018-19 has been spent; however, all $1 million allocated for 2019-20 is projected to be spent. The 2019-20 Budget does not include additional resources. AB 715 (Nazarian), Chapter 806, Statutes of 2019, extended the CPDR to January 1, 2021.
According to DPH’s website, as of March 9,, 2020, the CPDR has received 222,708 records since mandated reporting began in July 1, 2018. DPH notes that the number of records reported to the CPDR does not represent the number of individual’s with Parkinson’s disease in California, and states that it continues to process registry data, including de-duplication of case records and other quality control measures.
- SUPPORT. According to supporters, including the Michael J. Fox Foundation, sponsor of this bill, the American Parkinson’s Disease Foundation and the Parkinson Association of Northern California, this bill is critical for many reasons including: helping identify high-risk groups, support patient contact studies, and serve as a valuable data resource to prevent and optimally manage Parkinson’s disease; accurately determine incidence and prevalence of Parkinson’s disease in California; help researchers study patterns of Parkinson’s disease over time; and help determine if certain regions of the state that use more pesticides (based on CA’s pesticide registry) have higher incidents of Parkinson’s.
- OPPOSE UNLESS AMENDED. The California Medical Association has an oppose unless amended position and states that this bill should direct DPH to collect and report data on Parkinson’s disease only until the Office of Statewide Health Planning and Development’s (OSHPD) Heath Care Payments Database is implemented.
- OPPOSITION. The California Academy of Family Physicians opposes this bill and states that before extending the sunset date on the program, DPH should go through a rigorous re-evaluation of the CPDR and whether or not it is achieving results in addressing a noncommunicable disease.
REGISTERED SUPPORT / OPPOSITION:
Support
Michael J. Fox Foundation (sponsor)
ALS Association Golden West Chapter
American Parkinson Disease Association
California Life Sciences Association
Parkinson Association of Northern California
Parkinson and Movement Disorder Alliance
PD Active
Parkinson’s Foundation
Opposition
California Academy of Family Physicians
Analysis Prepared by: Rosielyn Pulmano / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):